Soft tissue

ABANZA Strengthens US Operations with Established Orthopedic Industry Expert, John Rizzo, as Executive Vice President

Retrieved on: 
Monday, January 22, 2024
Senior, Acquisition, Executive, Soft tissue, Zimmer Biomet, Growth, Management

NAVARRA, Spain, Jan. 22, 2024 /PRNewswire/ -- ABANZA is excited and honored to announce the strategic addition of Executive Vice President for US operations, JOHN RIZZO.

Key Points: 
  • NAVARRA, Spain, Jan. 22, 2024 /PRNewswire/ -- ABANZA is excited and honored to announce the strategic addition of Executive Vice President for US operations, JOHN RIZZO.
  • With a distinguished career spanning over three decades in the orthopedic medical device industry, John Rizzo brings a wealth of experience in building successful teams and distribution channels, both in start-up ventures and mature growth scenarios.
  • Prior to joining ABANZA, Rizzo served as the Senior Vice President of Sales at Embody Inc., playing a pivotal role in the company's transformation from pre-revenue to a successful acquisition by Zimmer Biomet in February 2023.
  • As ABANZA welcomes John Rizzo to its leadership team, the company is gearing up for an exciting phase of growth in the US market.

BioAtla Reports Second Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, August 1, 2023
WCLC, Therapy, CAB, LMS, Lung cancer, G&A, Research, Conditional, Soft tissue, AXL, SAN, Melanoma, Webcast, Food and Drug Administration, R, Infrared spectroscopy correlation table, FDA, Conference, Food, Vaccine, Pharmaceutical industry, Platinum, Cryptocurrency, NSCLC, Patient

Research and development (R&D) expenses were $31.0 million for the quarter ended June 30, 2023 compared to $20.7 million for the same quarter in 2022.

Key Points: 
  • Research and development (R&D) expenses were $31.0 million for the quarter ended June 30, 2023 compared to $20.7 million for the same quarter in 2022.
  • General and administrative (G&A) expenses were $6.2 million for the quarter ended June 30, 2023 compared to $8.3 million for the same quarter in 2022.
  • Net loss for the second quarter ended June 30, 2023 was $35.8 million compared to a net loss of $28.9 million for the same quarter in 2022.
  • The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, August 1, 2023, at 4:30 pm Eastern Time.

BioAtla Reports First Quarter 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Thursday, May 11, 2023
Therapy, CAB, LMS, Head, G&A, Lung cancer, Conditional, ASCO, CTC, Soft tissue, American Society of Clinical Oncology, AXL, Team Impulse, SAN, Annual general meeting, Webcast, Recurrence, R, PD-1, Research, FDA, Adenocarcinoma, Society, Food, Pharmaceutical industry, Vaccine, Platinum, Cryptocurrency, NSCLC, Patient

Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.

Key Points: 
  • Research and development (R&D) expenses were $21.7 million for the quarter ended March 31, 2023 compared to $16.9 million for the same quarter in 2022.
  • General and administrative (G&A) expenses were $7.2 million for the quarter ended March 31, 2023 compared to $7.4 million for the same quarter in 2022.
  • Net loss for the first quarter ended March 31, 2023 was $27.5 million compared to a net loss of $24.3 million for the same quarter in 2022.
  • The management of BioAtla, Inc. will host a conference call and webcast for the investment community today, May 11, 2023, at 4:30 pm Eastern Time.

BioAtla Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Progress

Retrieved on: 
Thursday, March 23, 2023
TIP, TMP, AACR, Therapy, CAB, LMS, Nivolumab, Metastasis, ESMO, Liquid biopsy, DLT, Progression-free survival, G&A, Oncology, Research, Lung cancer, ELCC, PFS, European Society for Medical Oncology, Conditional, FPI, Congress, American Association for Cancer Research, Soft tissue, EGFR, SAN, Webcast, UPS, Observation, Spacecraft, European Society of Gynaecological Oncology, R, FDA, IND, ORR, Food, Safety, ALK, Vaccine, Pharmaceutical industry, Nursing, Cryptocurrency, NSCLC, Patient

Research and development (R&D) expenses were $21.9 million for the quarter ended December 31, 2022 compared to $16.5 million for the same quarter in 2021.

Key Points: 
  • Research and development (R&D) expenses were $21.9 million for the quarter ended December 31, 2022 compared to $16.5 million for the same quarter in 2021.
  • General and administrative (G&A) expenses were $6.7 million for the quarter ended December 31, 2022 compared to $7.0 million for the same quarter in 2021.
  • Net loss for the quarter ended December 31, 2022 was $27.5 million compared to a net loss of $23.4 million for the same quarter in 2021.
  • Net loss for the full year 2022 was $106.5 million as compared to a net loss of $95.4 million in 2021.

Exactech Unveils the Future of Soft Tissue Management with First Surgeries Using Newton™, an Active Intelligence® Technology

Retrieved on: 
Monday, August 30, 2021
Medical Devices, Health, Technology, Surgery, Other Technology, Software, Newton, University, Twitter, Instagram, Joint, Surgeon, Intelligence, Future, Physician, Stanford University Medical Center, Hospital, Percussion section, Multimedia, First, Motion, Adult, Soft tissue, Patient, YouTube, LinkedIn, Patella, Active, Technology, Dentistry, 3D printing

View the full release here: https://www.businesswire.com/news/home/20210830005384/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210830005384/en/
    Exactech Unveils the Future of Soft Tissue Management with First Surgeries Using Newton, an Active Intelligence Technology (Photo: Business Wire)
    First surgeries were performed by Hari K. Parvataneni, MD, professor of orthopaedic surgery at the University of Florida, and James Huddleston III, MD, professor of orthopaedic surgery and chief of the adult reconstruction service at Stanford University Medical Center.
  • According to Huddleston, Soft tissue management is an area of opportunity for progression in orthopaedics, and Exactech is leading the way.
  • Newton is an innovative intra-articular device that engages the patients soft tissue to help surgeons execute a personalized, well-balanced total knee replacement.
  • The technology is in pilot launch in the US with expanded availability planned before the end of the year.

TELA Bio to Participate in Canaccord Genuity’s 41st Annual Growth Conference

Retrieved on: 
Tuesday, August 3, 2021
Canaccord Genuity, Tela, Soft tissue, Service companies

MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in Canaccord Genuitys 41st Annual Growth Conference.

Key Points: 
  • MALVERN, Pa., Aug. 03, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the Company will participate in Canaccord Genuitys 41st Annual Growth Conference.
  • TELA Bio's management is scheduled to present at Canaccord Genuitys 41st Annual Growth Conference on Thursday, August 12, 2021 at 2:00 PM EDT.
  • Interested parties can access the live and archived webcast at ir.telabio.com .
  • TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction.

Japan’s Kewpie Corporation, Pioneer of the Hyaluronic Acid Revolution, Has Just Revealed Its Mechanism

Retrieved on: 
Wednesday, July 28, 2021
Research, Biotechnology, Other Health, Alternative medicine, Health, Pharmaceutical, General Health, Other Science, Science, Branches of biology, Anatomy, Soft tissue, Acids, Glycosaminoglycans, Hyaluronic acid, Sanofi, Kewpie, Cornea, Skin

Now Kewpie Corporation has forged new ground by releasing heretofore unknown evidence of how that works.

Key Points: 
  • Now Kewpie Corporation has forged new ground by releasing heretofore unknown evidence of how that works.
  • In June of this year Kewpie addressed that same ISHAS conference, and it once again changed the game.
  • As hyaluronan activates the collagenic cycle beneath the corneal layer of the skin, its loss disrupts the skins ability to maintain moisture.
  • This responsibility is central to Kewpie Corporations credo, and it makes Hyabest(S)LF-P, its producer and culture singular in the field.

TELA Bio to Announce Second Quarter 2021 Financial Results

Retrieved on: 
Wednesday, July 28, 2021
Tela, Soft tissue

MALVERN, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the company will report second quarter 2021 financial results on Wednesday, August 11, 2021.

Key Points: 
  • MALVERN, Pa., July 28, 2021 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA"), a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction, today announced that the company will report second quarter 2021 financial results on Wednesday, August 11, 2021.
  • TELA Bios management will host a conference call and webcast at 4:30 p.m.
  • ET that day to discuss the financial results and provide a corporate update.
  • TELA Bio, Inc. (NASDAQ: TELA) is a commercial-stage medical technology company focused on designing, developing, and marketing innovative tissue reinforcement materials to address unmet needs in soft tissue reconstruction.

Integra LifeSciences Receives Innovative Technology Contract from Vizient for SurgiMend® Collagen Matrix for Soft Tissue Reconstruction

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Biomechanics, Soft tissue, Collagen, Integra

PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, announced its SurgiMend Collagen Matrix for Soft Tissue Reconstruction has received an Innovative Technology contract from Vizient, Inc. the nations largest member-driven health care performance improvement company.

Key Points: 
  • PRINCETON, N.J., July 14, 2021 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, announced its SurgiMend Collagen Matrix for Soft Tissue Reconstruction has received an Innovative Technology contract from Vizient, Inc. the nations largest member-driven health care performance improvement company.
  • Innovative Technology contracts are recommended after review and interaction with products submitted through Vizients Innovative Technology Program.
  • We are pleased that Vizient has selected SurgiMend as an innovative technology, said Dean Sollami, vice president of sales at Integra.
  • Our member council determined that SurgiMend Collagen Matrix for Soft Tissue Reconstruction met this standard and recognizes its potential to improve quality outcomes.

Wearable Ultrasounds Poised to Revolutionize Healing and Pain Management Healthcare Market

Retrieved on: 
Tuesday, June 29, 2021
Classical mechanics, Medical ultrasonography, Mechanics, Medicine, Acoustics, Athletic training, Therapeutic ultrasound, Ultrasound, Low-intensity pulsed ultrasound, Osteochondritis dissecans, Soft tissue

The result, Sustained Acoustic Medicine (sam), was found to be capable of altering the trajectory of soft tissue cells to stimulate remodeling and healing.

Key Points: 
  • The result, Sustained Acoustic Medicine (sam), was found to be capable of altering the trajectory of soft tissue cells to stimulate remodeling and healing.
  • Initially commercialized for the veterinary market in 2010, the company's productULTROZwas used to heal soft tissue injuries in dogs and horses.
  • By 2014, ZetrOZ had pivoted to exclusively serve the human market, building on an existing low-intensity pulsed ultrasound medical technology called Exogen.
  • Their flagship product, sam, is an in-home, ultrasound treatment that reduces the need for pain medication and surgery.